These engineered molecules simultaneously bind tumor-associated antigens and immune receptors, such as CD3 on T cells, while incorporating co-stimulatory signals through molecules like 4-1BB (CD137), OX40 (CD134), or CD28. This evidence concerns the gene TNFRSF9 and neoplasm.